Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT‐enhancer binding protein beta and hypoxia‐inducible factor‐2α and subsequent secretion of interleukin‐6, interleukin‐8, and vascular endothelial growth factor in the Caki‐1 clear cell renal cell carcinoma cell line

Abstract It has been previously established that hypoxia leads to tumor development, treatment resistance, and a poor prognosis. Under oxygen deprivation, hypoxia‐inducible factors (HIFs) are stimulated to activate the genes necessary for tumor development in a low‐oxygen environment. These genes encode regulators of angiogenesis, epithelial‐mesenchymal transition, and cellular metabolism. A disulfide isomerase, anterior gradient 2 (AGR2), has been shown to increase hypoxia‐inducible factor 1, alpha subunit (HIF‐1α) stability in breast cancer. Our goal was to determine if AGR2 affects the level of transcription factor hypoxia‐inducible factor 2, alpha subunit (HIF‐2α). As a model, we used the clear cell renal cell carcinoma (ccRCC) cell line Caki‐1. The cells were transduced with lentiviral vector (Tet‐On) encoding AGR2. After induction of AGR2 expression, cells were grown under either hypoxic (0.5% O 2 ) or normoxic (21% O 2 ) conditions. Our data showed that AGR2 upregulated both HIF‐1α and HIF‐2α expression in Caki‐1 cells increasing the expression of HIF‐activated genes (glucose transporter 1, phosphoglycerate kinase 1, vascular endothelial growth factor A, and transforming growth factor‐alpha) under the hypoxic conditions. Under the normoxic conditions, AGR2 strongly activated CCAAT‐enhancer binding protein beta (C/EBPβ). Upregulation of C/EBPβ correlated with increased expression and secretion of the interleukin‐6 and interleukin‐8, inducing angiogenesis and inflammation in Caki‐1 cells. In summary, our studies revealed that AGR2 has essential functions in ccRCC progression through upregulation of C/EBPβ and HIF‐2α expressions, which affects cell signaling and metabolism.